Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 174 results for "mirati"

Mirati Therapeutics, Inc. (MRTX) Upgraded to Hold by Zacks Investment Research
Ticker Report

Mirati Therapeutics, Inc. (MRTX) Upgraded to Hold by Zacks Inv...

Mirati Therapeutics, Inc. (NASDAQ:MRTX) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Monday, MarketBeat reports. According to Zacks, Mirati Therapeutics, Inc. is a ... Ticker Report, 5 hours ago
Mirati Therapeutics, Inc. (MRTX) Lifted to Hold at Zacks Investment Research American Banking News - Stock Ratings, 4 hours ago

Khalil named AFC Player of the Year - Japan claim women's team honour

(MENAFN - Arab Times) mirati Ahmed Khalil got a modicum of revenge on Guangzhou Evergrande captain Zheng Zhi when he pipped the Chinese to the Asian Football Confederation (AFC) Player of the Year award on Sunday. Khalil's Al Ahli club finished ...
 MENAFN21 hours ago

EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

Form EFFECT - Notice of Effectiveness SEC Accession No. 9999999995-15-003088 Accepted 2015-11-19 00:15:12 Documents 1 Effectiveness Date 2015-11-18 Registration Form S-3 Document Format Files Seq Description Document Type Size 1 primary_doc.html ...
 SEC1 week ago S-3 - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC3 weeks ago 10-Q - Mirati Therapeutics, Inc. (0001576263) (Filer)  SEC3 weeks ago

Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update

SAN DIEGO , Nov. 6, 2015 /PRNewswire/ --Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its drug development programs. "Over the last ...
 ADVFN India3 weeks ago Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update  BioSpace3 weeks ago AstraZeneca PLC 3rd Quarter Results  ADVFN UK3 weeks ago

Mirati Therapeutics Coverage Initiated by Analysts at Citigroup Inc. (MRTX)

Filed Under: Analysts New Coverage • Market News Stock analysts at Citigroup Inc. assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) in a research note issued on Monday, The Fly reports. The brokerage set a neutral rating on the ...
 American Banking News1 day ago Citigroup Initiates Mirati Therapeutics (NASDAQ:MRTX) Coverage With Neutral Rating  Octafinance6 days ago Citigroup Inc. Initiates Coverage on Mirati Therapeutics (MRTX)  Ticker Report1 week ago Mirati Therapeutics Receives New Coverage from Analysts at Citigroup Inc. (MRTX)  SleekMoney1 week ago

Company Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) Drops by -8.88%

Mirati Therapeutics, Inc. (NASDAQ:MRTX) has dropped 8.88% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 9.28% in the last 4 weeks. The shares have underperformed the S&P 500 by ...
 OTC Outlook1 week ago
Ticker Report

Brokerages Set Mirati Therapeutics Price Target at $46.50 (NASDAQ:MRTX)

Shares of Mirati Therapeutics (NASDAQ:MRTX) have been given a consensus recommendation of Buy by the nine ratings firms that are currently covering the company, Analyst Ratings reports. Two analysts have rated the stock with a hold ...
 SleekMoney1 week ago Mirati Therapeutics Receives $46.33 Consensus Target Price from Analysts (NASDAQ:MRTX)  SleekMoney1 month ago Mirati Therapeutics Given Consensus Rating of Buy by Brokerages (NASDAQ:MRTX)  American Banking News - Forex1 month ago
Ticker Report

Mirati Therapeutics Given Average Recommendation of Buy by Analysts (NASDAQ:MRTX)

Filed Under: Consensus Rating Articles • Market News Mirati Therapeutics (NASDAQ:MRTX) has been assigned an average rating of Buy from the nine brokerages that are covering the firm, Analyst Ratings Net reports. Two research analysts have rated ...
 American Banking News1 week ago Mirati Therapeutics Receives Average Recommendation of Buy from Brokerages (NASDAQ:MRTX)  Ticker Report1 month ago
Ticker Report

Mirati Therapeutics Downgraded to Buy at Vetr Inc. (MRTX)

Mirati Therapeutics (NASDAQ:MRTX) was downgraded by stock analysts at Vetr from a strong-buy rating to a buy rating in a research report issued to clients and investors on Tuesday, AnalystRatings.NET reports. They currently have a $46.96 price ...
 American Banking News2 weeks ago Mirati Therapeutics Downgraded by Vetr Inc. to Buy (MRTX)  SleekMoney2 weeks ago

Mirati Therapeutics, Inc. Price Target Update

Mirati Therapeutics, Inc. (NASDAQ:MRTX): The mean short term price target for Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been established at $46.6 per share. The higher price target estimate is at $50 and the lower price target estimate is expected ...
 OTC Outlook2 weeks ago Analyst Price Target Update on Mirati Therapeutics, Inc.  OTC Outlook3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less